nonalcoholic fatty liver disease
present FLD disease
widespread disease
liver cancer
therapeutic agent
Nonalcoholic steatohepatitis
potent Micro-RNA therapeutic
general population
clinical trials
pre-clinical studies
NAFLD
huge perportion
prompt treatment
major health benefits
technology
order
cirrhosis
pharmaceutical company
microRNA
mouse model
pathogenesis of